ABBV-722

N/A

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameABBV-722
Drug Alias NameABBV-722
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A